[Effect of type 2 innate lymphocytes on Treg and CD8+ T cell function through IL-9 in chronic lymphocytic leukemia]

Ruixue Yang1, Xuejiao Zeng2, Jianhua Qu3

  • 1Center of Hematology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054; Hematology Institute of Xinjiang Uygur Autonomous Region, Urumqi 830054; Hematology Clinical Research Center of Xinjiang Uygur Autonomous Region, Urumqi 830054, China.

Insights

Type 2 innate lymphocytes (ILC2) and interleukin-9 (IL-9) are elevated in chronic lymphocytic leukemia (CLL), impairing CD8+ T cell anti-tumor activity and promoting Treg immunosuppression, thus contributing to CLL progression.

Area of Science:

  • Immunology
  • Hematology
  • Oncology

Context:

  • Chronic lymphocytic leukemia (CLL) is a B-cell malignancy characterized by immune dysregulation.
  • Type 2 innate lymphocytes (ILC2) and their cytokine product, interleukin-9 (IL-9), are implicated in various immune responses but their role in CLL remains unclear.

Purpose:

  • To investigate the differences in ILC2 and IL-9 levels between CLL patients and healthy controls.
  • To elucidate the impact of ILC2-derived IL-9 on regulatory T cells (Tregs), CD8+ T cells, and CLL cells.

Summary:

  • Elevated levels of ILC2, Tregs, and IL-9 were observed in CLL patients compared to healthy controls.
  • ILC2 from CLL patients produced higher levels of IL-9.
  • Neutralization of IL-9 reduced Treg suppressive markers (PD-1, TIGIT), enhanced CD8+ T cell cytotoxic markers (granzyme B), and increased apoptosis of MEC-1 (CLL) cells.

Impact:

  • ILC2-derived IL-9 contributes to CLL pathogenesis by suppressing anti-tumor CD8+ T cell responses and promoting Treg-mediated immunosuppression.
  • Targeting the IL-9 pathway may represent a novel therapeutic strategy for chronic lymphocytic leukemia.